MUNICH, GERMANY--(Marketwire - May 31, 2012) - MorphoSys AG (FRANKFURT: MOR) (Prime
Standard Segment, TecDAX) announced today that at
the Company's Annual Shareholder Meeting on Thursday, May 31,
shareholders confirmed the appointment of Ms. Karin Eastham and Dr. Marc
as new members of the Supervisory Board. Ms. Eastham and Dr. Cluzel
Prof. Dr. Jürgen Drews and Dr. Metin Colpan. Prof. Drews has been a
MorphoSys AG's Supervisory Board since 1998, while Dr. Colpan joined in
"We are pleased to announce the election of two experienced new members
Supervisory Board and look forward to working with them," commented Dr.
Möller, Chairman of the Supervisory Board of MorphoSys AG. "On
behalf of the
Company, I would like to thank Professor Drews and Dr. Colpan for
invaluable support in establishing MorphoSys as one of the world's
The shareholders of MorphoSys AG approved the following substantive
proposals put to vote at the meeting:
- Granting full discharge of the members of the Management and
Boards in respect of their activities during the business year 2011.
- The re-appointment of Dr. Gerald Möller, Dr. Daniel Camus and Dr.
Vernon to the Company's Supervisory Board. Following the AGM, the
the Supervisory Board re-elected Dr. Möller as Chairman. Mr.
elected Vice Chairman.
- The appointment of PricewaterhouseCoopers AG as auditors of the Company
the MorphoSys Group for the business year 2012.
- The use of the net earnings of MorphoSys AG; Management and Supervisory
Boards recommended that the net profit of the business year 2011 is
forward as accumulated income.
At the Annual General Meeting 2012 of MorphoSys AG, 39.7% of the voting
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®),
CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE